| Autor: |
Julio García-Cordero, Juvenal Mendoza-Ramírez, David Fernández-Benavides, Daniela Roa-Velazquez, Jessica Filisola-Villaseñor, Sandra Paola Martínez-Frías, Erik Saul Sanchez-Salguero, Carlos E. Miguel-Rodríguez, Jose L. Maravillas Montero, Jose J. Torres-Ruiz, Diana Gómez-Martín, Leopoldo Santos Argumedo, Edgar Morales-Ríos, Juan M. Alvarado-Orozco, Leticia Cedillo-Barrón |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Diagnostics, Vol 11, Iss 10, p 1808 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2075-4418 |
| DOI: |
10.3390/diagnostics11101808 |
| Popis: |
The coronavirus disease 2019 (COVID-19) pandemic has reached an unprecedented level. There is a strong demand for diagnostic and serological supplies worldwide, making it necessary for countries to establish their own technologies to produce high-quality biomolecules. The two main viral antigens used for the diagnostics for severe acute respiratory syndrome coronavirus (SARS-CoV-2) are the structural proteins spike (S) protein and nucleocapsid (N) protein. The spike protein of SARS-CoV-2 is cleaved into S1 and S2, in which the S1 subunit has the receptor-binding domain (RBD), which induces the production of neutralizing antibodies, whereas nucleocapsid is an ideal target for viral antigen-based detection. In this study, we designed plasmids, pcDNA3.1/S1 and pcDNA3.1/N, and optimized their expression of the recombinant S1 and N proteins from SARS-CoV-2 in a mammalian system. The RBD was used as a control. The antigens were successfully purified from Expi293 cells, with high yields of the S1, N, and RBD proteins. The immunogenic abilities of these proteins were demonstrated in a mouse model. Further, enzyme-linked immunosorbent assays with human serum samples showed that the SARS-CoV-2 antigens are a suitable alternative for serological assays to identify patients infected with COVID-19. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
